Axon Enterprise (NASDAQ:AXON) PT Raised to $375.00 at JMP Securities

Axon Enterprise (NASDAQ:AXON) had its price target upped by JMP Securities from $320.00 to $375.00 in a research report sent to investors on Wednesday morning, Benzinga reports. The firm currently has a market outperform rating on the biotechnology company’s stock.

Several other research firms have also issued reports on AXON. TheStreet lowered Axon Enterprise from a b rating to a c+ rating in a research report on Tuesday, February 27th. Robert W. Baird upped their price target on Axon Enterprise from $260.00 to $300.00 and gave the company an outperform rating in a research report on Thursday, February 22nd. Barclays upped their price target on Axon Enterprise from $296.00 to $308.00 and gave the company an overweight rating in a research report on Thursday, February 29th. JPMorgan Chase & Co. increased their target price on Axon Enterprise from $330.00 to $365.00 and gave the stock an overweight rating in a research report on Thursday, April 11th. Finally, Morgan Stanley raised their target price on Axon Enterprise from $285.00 to $310.00 and gave the company an equal weight rating in a research note on Friday, April 26th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of Moderate Buy and an average target price of $323.09.

Axon Enterprise Stock Performance

Axon Enterprise stock opened at $311.57 on Wednesday. The stock has a market cap of $23.51 billion, a P/E ratio of 135.47 and a beta of 0.91. The company has a current ratio of 3.00, a quick ratio of 2.66 and a debt-to-equity ratio of 0.42. The stock has a 50 day moving average of $306.01 and a 200-day moving average of $263.59. Axon Enterprise has a 52 week low of $175.37 and a 52 week high of $329.87.

Axon Enterprise (NASDAQ:AXON) last released its earnings results on Tuesday, February 27th. The biotechnology company reported $0.77 EPS for the quarter, beating the consensus estimate of $0.48 by $0.29. The company had revenue of $432.14 million during the quarter, compared to analysts’ expectations of $418.97 million. Axon Enterprise had a return on equity of 14.11% and a net margin of 11.14%. On average, analysts expect that Axon Enterprise will post 2.44 EPS for the current fiscal year.

Institutional Investors Weigh In On Axon Enterprise

A number of hedge funds and other institutional investors have recently modified their holdings of AXON. AE Wealth Management LLC raised its stake in shares of Axon Enterprise by 32.4% during the third quarter. AE Wealth Management LLC now owns 1,775 shares of the biotechnology company’s stock valued at $353,000 after purchasing an additional 434 shares in the last quarter. Asset Management One Co. Ltd. raised its stake in shares of Axon Enterprise by 7.5% during the third quarter. Asset Management One Co. Ltd. now owns 29,085 shares of the biotechnology company’s stock valued at $5,788,000 after purchasing an additional 2,030 shares in the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in shares of Axon Enterprise by 21.0% during the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 17,300 shares of the biotechnology company’s stock valued at $3,443,000 after purchasing an additional 3,000 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its holdings in Axon Enterprise by 8.9% during the third quarter. Cambridge Investment Research Advisors Inc. now owns 7,716 shares of the biotechnology company’s stock worth $1,535,000 after acquiring an additional 630 shares during the period. Finally, Xponance Inc. grew its holdings in Axon Enterprise by 1.1% during the third quarter. Xponance Inc. now owns 16,518 shares of the biotechnology company’s stock worth $3,287,000 after acquiring an additional 186 shares during the period. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.